Chicago, ILNCT06914648Now EnrollingIRB Ready

Primary Liver Cancer Clinical Trial in Chicago, IL

Access cutting-edge primary liver cancer treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Maastricht University

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access primary liver cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related primary liver cancer treatment provided free

Apply for This Chicago Location

Check if you qualify for this primary liver cancer clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Primary Liver Cancer Study in Chicago

The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma. The main questions this trial aims to answer are whether combined PVE and HVE increases the proportion of patients who become resectable within 3 weeks and improves 5-year overall survival compared to PVE alone by enhancing liver hypertrophy. Participants will: * Undergo either standard PVE or combined PVE and HVE. * Have regular imaging to assess liver resectability. * Be monitored for survival outcomes up to 5 years after intervention.

Sponsor: Maastricht University

Who Can Participate

Inclusion Criteria

PLC diagnosis, specifically iCCC, pCCC, and HCC;
Requiring PVE due to an FLR volume is \<30% in normally functioning livers, \<40% in livers with potentially impaired function e.g. resulting from prior systemic therapy induction or bile duct colonization / transpapillary biliary drainage, or \<50% in livers with severely impaired function resulting from liver cirrhosis (max. Child Pugh A5) OR function on hepatobiliary scintigraphy (HEBIS) is \< 2.7 %/min/m2;
Age ≥ 18 years;
Able to understand the trial and provide informed consent.

Exclusion Criteria

Liver cirrhosis with a Child-Pugh score of B or C;
Presence of portal hypertension;
Presence of cholangitis;
Pregnant women;
Premenopausal females not able/willing to commit to contraception (specifically long-acting reversible contraception or hormonal contraception);
Patients unresectable due to prohibitive comorbidities (decision made by local multidisciplinary team);
Patients with hepatic malignancies other than iCCC, pCCC or HCC;
PVE/HVE anatomically not feasible;
Any patient with non-resectable or non-ablatable extrahepatic metastatic disease.
Unable to understand the study information, study instructions and give informed consent

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT06914648) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Primary Liver Cancer Treatment Options in Chicago, IL

If you're searching for primary liver cancer treatment options in Chicago, IL, this clinical trial (NCT06914648) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced primary liver cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all primary liver cancer clinical trials near you to find additional studies recruiting in your area.

More Liver Cancer Trials in Chicago, IL

See all liver cancer clinical trials recruiting in Chicago — not just this study.

Browse Liver Cancer Trials in Chicago →

Browse More Trials by Condition

Liver Cancer TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL